Progressive multifocal leukoencephalopathy genetic risk variants for pharmacovigilance of immunosuppressant therapies

Progressive multifocal leukoencephalopathy genetic risk variants for pharmacovigilance of immunosuppressant therapies

BackgroundProgressive multifocal leukoencephalopathy (PML) is a rare and often lethal brain disorder caused by the common, typically benign polyomavirus 2, also known as JC virus (JCV). In a small percentage of immunosuppressed individuals, JCV is reactivated and infects the brain, causing devastati...

Full description

Bibliographic Details
Main Authors: Eli Hatchwell, Edward B. Smith, Shapour Jalilzadeh, Christopher D. Bruno, Yassine Taoufik, Houria Hendel-Chavez, Roland Liblau, David Brassat, Guillaume Martin-Blondel, Heinz Wiendl, Nicholas Schwab, Irene Cortese, Maria Chiara Monaco, Luisa Imberti, Ruggero Capra, Jorge R. Oksenberg, Jacques Gasnault, Bruno Stankoff, Todd A. Richmond, David M. Rancour, Igor J. Koralnik, Barbara A. Hanson, Eugene O. Major, Christina R. Chow, Peggy S. Eis
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-12-01
Series:Frontiers in Neurology
Subjects:
immunodeficiency
JC virus
multiple sclerosis
natalizumab
pharmacovigilance
progressive multifocal leukoencephalopathy
Online Access:https://www.frontiersin.org/articles/10.3389/fneur.2022.1016377/full

Internet

https://www.frontiersin.org/articles/10.3389/fneur.2022.1016377/full

Similar Items